A predictive model and survival analysis for local recurrence in differentiated thyroid carcinoma

Yang, Peipei; Huang, JiuPing; Wang, Zhendong; Qian, Linxue

doi:10.23736/s2724-6507.21.03393-9

Cited by 3 publications

(1 citation statement)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thyroid tumor size is related to prognosis. Previous study ( 20 ) has reported that tumor diameter has a substantial impact on the prognosis of patients with DTC. In this study, tumor diameter was found to be an independent factor for predicting ER, suggesting that clinical attention should be paid to tumor size in patients with hyperthyroidism complicated with DTC.…”

Section: Discussionmentioning

confidence: 96%

Efficacy evaluation and influencing factor analysis of postoperative 131I for the treatment of primary hyperthyroidism combined with differentiated thyroid cancer (DTC)—a retrospective cohort study

Zhao¹,

Han²,

Lu³

et al. 2023

Gland Surg

View full text Add to dashboard Cite

Background 131 I treatment is one of the important methods of comprehensive postoperative treatment for patients with hyperthyroidism complicated with differentiated thyroid cancer (DTC). Early identification of patients with poor treatment efficacy of 131 I is particularly important. Current studies mainly focus on the relationship between hyperthyroidism and the occurrence and development of DTC, and there are few studies on the factors affecting the curative effect. The purpose of this study was to find the influencing factors of efficacy evaluation and provide evidence for early identification of patients with poor efficacy in DTC combined with primary hyperthyroidism patients. Methods This was a retrospective analysis of DTC patients with primary hyperthyroidism who received 131 I treatment in our department from 2012 to 2021. Follow-up intervals were 3 months within 1 year, 6 months within 1 to 2 years, and annual follow-up thereafter, the median follow-up time was 12.0 (3.0, 24.0) months. Serological examination and imaging examination were used to evaluate the efficacy. Patients were classified into an excellent response (ER) group and a non-ER group based on treatment response more than 6 months after 131 I treatment. Univariate analysis and multivariate logistic regression analysis were performed on the basic clinical characteristics, pathological characteristics and curative effect of the patients, in order to find independent risk factors affecting the curative effect. Results Eighty-nine patients were mostly female (80.9%), the average age was 43.47±11.88 years old, and tumor size was 1.2 (0.75, 1.80) cm, 56 patients (62.9%) in the ER group. psTg [odds ratio (OR): 1.325; 95% confidence interval (CI): 1.135–1.547; P<0.001], maximum tumor diameter (OR: 2.428; 95% CI: 1.392–4.235; P=0.002) and pathology-confirmed combined HT (OR: 8.669; 95% CI: 1.877–40.038; P=0.006) were independent risk factors for predicting ER. Conclusions Our findings demonstrate that most hyperthyroidism combined with DTC patients could get favorable clinical outcomes from 131 I treatment. The tumor diameter, pathology-confirmed diagnosis of combined HT, and psTg level can be used to identify patients who can get ER by the effect of 131 I in hyperthyroidism combined with DTC at an early stage.

show abstract

Section: Discussionmentioning

confidence: 96%

Efficacy evaluation and influencing factor analysis of postoperative 131I for the treatment of primary hyperthyroidism combined with differentiated thyroid cancer (DTC)—a retrospective cohort study

Zhao¹,

Han²,

Lu³

et al. 2023

Gland Surg

View full text Add to dashboard Cite

show abstract

Highlights of the April-June 2024 issue

VITALE

2024

Minerva Endocrinol

View full text Add to dashboard Cite

From sequencing to validation: NGS-based exploration of plasma miRNA in papillary thyroid carcinoma

Cui,

Xuan,

Liao

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

ObjectiveA non-invasive method using plasma microRNAs provides new insights into thyroid cancer diagnosis. The objective of this study was to discover potential circulating biomarkers of papillary thyroid carcinoma (PTC) through the analysis of plasma miRNAs using next-generation sequencing (NGS).MethodsPlasma miRNAs were isolated from peripheral blood samples collected from healthy individuals, patients diagnosed with PTC, and those with benign thyroid nodules. The Illumina NovaSeq 6000 platform was employed to establish the miRNA expression profiles. Candidate miRNAs for diagnostic purposes were identified utilizing the Random Forest (RF) algorithm. The selected miRNAs were subsequently validated in an independent validation set using RT-qPCR.ResultsNGS results revealed consistent plasma miRNA expression patterns among healthy individuals and patients with benign thyroid nodules in the discovery set (6 healthy cases, 17 benign cases), while differing significantly from those observed in the PTC group (17 PTC cases). Seven miRNAs exhibiting significant expression differences were identified and utilized to construct an RF classifier. Receiver operating characteristic (ROC) analysis for PTC diagnosis, and the area under the curve (AUC) was 0.978. Subsequent KEGG and GO analyses of the target genes associated with these 7 miRNAs highlighted pathways relevant to tumors and the cell cycle. Independent validation through RT-qPCR in a separate cohort (15 CONTROL, 15 PTC groups) underscored hsa-miR-301a-3p and hsa-miR-195-5p as promising candidates for PTC diagnosis.ConclusionIn conclusion, our study established a seven-miRNA panel in plasma by Random Forest algorithm with significant performance in discriminating PTC from healthy or benign group. hsa-miR-301a-3p, hsa-miR-195-5p in plasma have potential for further study in the diagnosis of PTC in Asian ethnic.

show abstract

A predictive model and survival analysis for local recurrence in differentiated thyroid carcinoma

Cited by 3 publications

References 29 publications

Efficacy evaluation and influencing factor analysis of postoperative 131I for the treatment of primary hyperthyroidism combined with differentiated thyroid cancer (DTC)—a retrospective cohort study

Efficacy evaluation and influencing factor analysis of postoperative 131I for the treatment of primary hyperthyroidism combined with differentiated thyroid cancer (DTC)—a retrospective cohort study

Highlights of the April-June 2024 issue

From sequencing to validation: NGS-based exploration of plasma miRNA in papillary thyroid carcinoma

Contact Info

Product

Resources

About